NBoc-DMT
| Clinical data | |
|---|---|
| Other names | NB-DMT; DMT-BOC; N′-t-BOC-DMT; N′-tert-BOC-DMT; tert-BOC-DMT; N′-tert-Butoxycarbonyl-N,N-dimethyltryptamine | 
| Drug class | Serotonergic psychedelic; Hallucinogen; Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist | 
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| 
 | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C17H24N2O2 | 
| Molar mass | 288.391 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
NBoc-DMT, or NB-DMT, also known as N1-tert-butoxycarbonyl-N,N-dimethyltryptamine, is a serotonergic psychedelic of the tryptamine family. It is a novel designer and recreational drug and is a synthetic modification of dimethyltryptamine (DMT) with an N′-tert-butyloxycarbonyl (NBoc) group.
NB-DMT is said to be a "prodrug" of DMT that decomposes into DMT when the compound is heated (e.g., with smoking or vaping). It may also be useful as an orally active prodrug of DMT, unlike DMT itself which is inactive when taken orally. NB-DMT has been claimed to have about 25% of the potency of DMT by weight.
It was first detected as a designer drug being sold online by February 2024. NB-DMT is a Schedule I controlled substance in Russia. A number of other NBoc designer drugs have also been encountered.